{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:26:17Z","timestamp":1790166377873,"version":"4.1.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated the antituberculosis (anti-TB) activity of five \u03b2-lactams alone or in combination with \u03b2-lactamase inhibitors against 41 clinical isolates of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium tuberculosis<\/jats:named-content>\n            , including multidrug-resistant and extensively drug-resistant strains. Of those, tebipenem, an oral carbapenem, showed the most potent anti-TB activity against clinical isolates, with a MIC range of 0.125 to 8 \u03bcg\/ml, which is achievable in the human blood. More importantly, in the presence of clavulanate, MIC values of tebipenem declined to 2 \u03bcg\/ml or less.\n          <\/jats:p>","DOI":"10.1128\/aac.03539-14","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T08:27:40Z","timestamp":1410856060000},"page":"7010-7014","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["<i>In Vitro<\/i>\n            Susceptibility of Mycobacterium tuberculosis Isolates to an Oral Carbapenem Alone or in Combination with \u03b2-Lactamase Inhibitors"],"prefix":"10.1128","volume":"58","author":[{"given":"Yasuhiro","family":"Horita","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Host Defense, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kazumi","sequence":"additional","affiliation":[{"name":"Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Host Defense, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Matsuyama, Kiyose, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2427"},{"key":"e_1_3_3_3_2","first-page":"307","article-title":"The totally drug resistant tuberculosis (TDR-TB)","volume":"6","author":"Velayati AA","year":"2013","unstructured":"VelayatiAAFarniaPMasjediMR. 2013. The totally drug resistant tuberculosis (TDR-TB). Int. J. Clin. Exp. Med. 6:307\u2013309.","journal-title":"Int. J. Clin. Exp. Med."},{"key":"e_1_3_3_4_2","volume-title":"Global tuberculosis report 2013","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Global tuberculosis report 2013. WHO, Geneva, Switzerland."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.4.1025"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0414"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis460"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00124312"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2816-2821.2005"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573398X113099990017"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks395"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167498"},{"key":"e_1_3_3_13_2","first-page":"754","article-title":"Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis\u2014evaluation of interlaboratory precision and interpretive compatibility with agar proportion method","volume":"47","author":"Yamane N","year":"1999","unstructured":"YamaneNIchiyamaSKawaharaSIinumaYSaitohHShimojimaMUdagawaHNakasoneI. 1999. Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis\u2014evaluation of interlaboratory precision and interpretive compatibility with agar proportion method. Rinsho Byori 47:754\u2013766.","journal-title":"Rinsho Byori"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_3_15_2","volume-title":"EUCAST clinical breakpoints table, version 3.1-2013-02-11","author":"EUCAST","year":"2013","unstructured":"EUCAST. 2013. EUCAST clinical breakpoints table, version 3.1-2013-02-11. EUCAST, V\u00e4xj\u00f6, Sweden."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-662"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5277-5285.2004"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.31.2.406-409.1993"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2620"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.735"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00023-13"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh050"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(80)91118-6","article-title":"Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study","author":"Ball AP","year":"1980","unstructured":"BallAPGeddesAMDaveyPGFarrellIDBrookesGR. 1980. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study. Lancet i:620\u2013623.","journal-title":"Lancet"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01663-13"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00239-08"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00665-12"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi701506h"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi500339j"},{"key":"e_1_3_3_29_2","first-page":"214","article-title":"Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals","volume":"62","author":"Kijima K","year":"2009","unstructured":"KijimaKMoritaJSuzukiKAokiMKatoKHayashiHShibasakiSKurosawaT. 2009. Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals. Jpn. J. Antibiot. 62:214\u2013240.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1248\/jhs.53.302"},{"key":"e_1_3_3_31_2","first-page":"155","article-title":"Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections","volume":"62","author":"Baba S","year":"2009","unstructured":"BabaSYamanakaNSuzukiKFurukawaMFuruyaNUbukataKTotsukaK. 2009. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn. J. Antibiot. 62:155\u2013177.","journal-title":"Jpn. J. Antibiot."},{"key":"e_1_3_3_32_2","first-page":"90","article-title":"Pharmacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers","volume":"57","author":"Nakashima M","year":"2009","unstructured":"NakashimaMMoritaJAizawaK. 2009. Pharmacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn. J. Chemother. 57:90\u201394.","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_3_33_2","first-page":"82","article-title":"Pharmacokinetics and safety of oral carbapenem antibiotic tebipenem pivoxil tablets in healthy male volunteers","volume":"57","author":"Nakashima M","year":"2009","unstructured":"NakashimaMMoritaJAizawaK. 2009. Pharmacokinetics and safety of oral carbapenem antibiotic tebipenem pivoxil tablets in healthy male volunteers. Jpn. J. Chemother. 57:82\u201389.","journal-title":"Jpn. J. Chemother."},{"key":"e_1_3_3_34_2","first-page":"38","article-title":"Antimicrobial activity of tebipenem pivoxil against Streptococcus pneumoniae and Haemophilus influenzae, and its pharmacokinetic-pharmacodynamic profile in mice","volume":"57","author":"Sugano T","year":"2009","unstructured":"SuganoTYoshidaTYamadaKShimizuAMoritaJKijimaKMaebashiKShibasakiS. 2009. Antimicrobial activity of tebipenem pivoxil against Streptococcus pneumoniae and Haemophilus influenzae, and its pharmacokinetic-pharmacodynamic profile in mice. Jpn. J. Chemother. 57:38\u201348.","journal-title":"Jpn. J. Chemother."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03539-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03539-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:48:49Z","timestamp":1645483729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03539-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1128\/AAC.03539-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03539-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}